Clinical Physiology Fundamental Concepts in Physiology Relevant to Clinical Practice

Total Page:16

File Type:pdf, Size:1020Kb

Clinical Physiology Fundamental Concepts in Physiology Relevant to Clinical Practice This page intentionally left blank This is an admirably concise and clear guide to Clinical Physiology fundamental concepts in physiology relevant to clinical practice. It covers all the body systems in an accessible style of presentation. Bulleted checklists and boxed information provide an easy overview and summary of the essentials. By concentrating on the core knowledge of physiology, it will serve as a useful revision aid for all doctors striving to achieve postgraduate qualification, and for anyone needing to refresh their knowledge base in the key elements of clinical physiology. The author’s own experience as an examiner at all levels has been distilled here for the benefit of postgraduate trainees and medical and nursing students. Dr Ashis Banerjee is Consultant in Emergency Medicine and serves as Examiner for those undertaking their MB, BS, MRCS and MFAEM examinations. Clinical Physiology An Examination Primer Ashis Banerjee Consultant in Emergency Medicine, Lewisham University Hospital cambridge university press Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo Cambridge University Press The Edinburgh Building, Cambridge cb2 2ru,UK Published in the United States of America by Cambridge University Press, New York www.cambridge.org Informationonthistitle:www.cambridge.org/9780521542265 © A. Banerjee 2005 This publication is in copyright. Subject to statutory exception and to the provision of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press. First published in print format 2005 isbn-13 978-0-511-12927-8 eBook (EBL) isbn-10 0-511-12927-0 eBook (EBL) isbn-13 978-0-521-54226-5 paperback isbn-10 0-521-54226-x paperback Cambridge University Press has no responsibility for the persistence or accuracy of urls for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate. Every effort has been made in preparing this publication to provide accurate and up-to-date information that is in accord with accepted standards and practice at the time of publication. Nevertheless, the authors, editors and publisher can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publisher therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use. Contents Preface page vii 1 Cell physiology 1 2 Water and electrolyte balance 19 3 Acid–base balance 31 4 Renal physiology 44 5 Temperature regulation 66 6 Cardiovascular system 71 7 Respiratory system 115 8 Blood 140 9 Neurophysiology 177 10 Endocrine physiology 258 11 Gastrointestinal physiology 316 Index 349 v Preface The teaching of physiology at the undergraduate level often fails to provide its students with any enthusiasm or lasting zeal for the subject. This is regrettable because a good knowledge of normal human physiology is critically important in understanding the effects of organ dysfunction secondary to disease. Adequate treatment of the multiple insults to the body in the seriously ill patient requires a good understanding of the underlying pathophysiological mechanisms. Undoubtedly, the gradual demise of academic physiology in the United Kingdom has contributed to the current state of affairs. This book explains the basic concepts of physiology in a succinct and didactic fashion. Its aim is to aid the medical student and the junior doctor in obtaining a good understanding of the homeostatic mechanisms of the human body so that the effects of dysfunction of these mechanisms can be better understood. It is also designed to aid with the basic science component of the various royal college examinations that are required to be passed prior to entering specialist training in the United Kingdom. Ashis Banerjee vii Cell physiology 1 & Introduction The cell is the structural and functional unit of life. Bounded by a cell mem- brane, which maintains the homeostasis of the cell interior, it contains various membrane-bound compartments or organelles within, which subserve specia- lised functions. These membrane-bound organelles are characteristic of all eukaryotic cells, including those in humans. & Cell membrane The cell membrane bounds all cells in the human body, forming a dynamic interface between the intracellular and extracellular environments. It serves, or facilitates, the following functions: * The maintenance of cell shape and structure. This is achieved by the pre- sence of anchoring sites for cytoskeletal filaments and extracellular matrix components. * A transport function. This is brought about by selective permeability to ions and macromolecules, allowing the maintenance of cytosolic ionic composi- tion, osmotic pressure and pH (around 7.2–7.4). * Intercellular communication, involving signal transduction, i.e. the detec- tion of chemical signals (messengers) from other cells. These signals mediate nerve transmission, hormone release, muscle contraction and the stimulation of growth. This is the result of the binding of signalling molecules by trans- membrane receptors. * Intercellular adhesion. This is brought about by the fusion of the membrane with other cell membranes via specialised junctions. * Directed cell movement. 1 Cell physiology Structure of cell membranes The thickness of cell membranes ranges from 6–10 nm, typically being about 7.5 nm. * One nanometre is equal to 10À9 metre. Cell membranes are composed primarily of lipids and proteins. Lipids are the major components of membranes, including glycerophospholipids (phospho- glycerides), sphingolipids (sphingomyelin) and cholesterol. Cephalin (phospha- tidylethanolamine) and lecithin (phosphatidylcholine) are the most common glycerophospholipids in membranes. Membrane lipids form self-sealing bilayers. They are amphipathic molecules, with hydrophobic and hydrophilic moieties. The hydrophobic groups, the long fatty acyl side chains, form the core, with the polar hydrophilic groups lining both surfaces. Carbohydrates comprise 5%–10% of cell membranes. They consist of glyco- lipids and glycoproteins and form the glycocalyx coat on the surface of the plasma membrane. This layer is responsible for the immunological characteristics of the cell and carries surface receptors that are involved in molecular recognition. According to the fluid mosaic model of Singer and Nicolson cell membranes possess fluid structures, being considered as two-dimensional solutions of oriented globular proteins and lipids. They take the form of a continuous fluid but stable lipid bilayer, studded with an array of membrane-associated or membrane- spanning proteins. The fluidity of the membrane is determined by the degree of unsaturation of the constituent fatty acids. The lipids and proteins can undergo rotational and lateral movement.Membranes are structurally and functionally asymmetrical. This is due to asymmetrical orientation of integral and peripheral membrane proteins, laterally and transversely. Membranes are also electrically polarised, with the inside being negative with respect to the exterior. On electron microscopy, a trilaminar structure is evident. This consists of two dark outer bands, representing the polar heads of the membrane phospholipids and protein molecules on the inner and outer surfaces of the membrane, and an inner lighter band due to the nonpolar tails of the lipid molecules. Membrane proteins Classification of membrane proteins Membrane proteins can be classified according to their structural relationship to the lipid bilayer into: Integral proteins, which penetrate the lipid bilayer; Peripheral or extrinsic proteins, which are located outside the lipid bilayer; 2 Cell membrane Membrane protein functions Transport carriers in facilitated diffusion processes; Ion channels; Pumps involved in active transport; Receptors for hormones and neurotransmitters, e.g. G-proteins, which act as mole- cular switches: signal transduction; Cell to cell recognition and interaction; Junctional proteins in intercellular junctions: cell adhesion molecules; Second messenger enzymes. Lipid-anchored proteins, which lie outside the lipid bilayer but are covalently linked to lipid molecules within the bilayer. Properties of integral membrane proteins Integral membrane proteins demonstrate asymmetrical orientation in the mem- brane. They are amphipathic, with both hydrophobic and hydrophilic regions. If they span the membrane, they are known as transmembrane proteins. Removal from the membrane can be achieved by denaturation of the membrane, using either a detergent, e.g. ionic detergent sodium tetradecyl sulphonate, or the non-ionic detergent Triton X-100, or an organic solvent. Examples of integral membrane proteins include hormone receptors, ion channels, gap junction proteins, Naþ/Kþ-ATPase and histocompatibility antigens. Classification of cell membrane receptors Cell membrane receptors are classified according to the signal transduction mechanism involved into: * Ion channel-linked (ionotropic) receptors, which are coupled directly to ligand-gated ion channels. Examples include nicotinic acetylcholine recep- tors, ionotropic glutamate receptors,
Recommended publications
  • Guidelines for Transfusions
    Guidelines for Transfu- sion Prepared by: Community Transfusion Committee Lincoln, Nebraska CHAIR: Aina Silenieks, MD MEMBERS: L. Bausch, M.D. R. Burton, M.D. S. Dunder, M.D. D. Voigt, M.D. B. J. Wilson, M.D. COMMUNITY Becky Croner REPRESENTATIVES: Ellen DiSalvo Christa Engel Phyllis Ericson Kelly Gillaspie Pat Gilles Vic Grdina Jessica Henrichs Kelly Jensen Laurel McReynolds Christina Nickel Angela Novotny Kelley Thiemann Janet Wachter Jodi Wikoff Guidelines For Transfusion Community Transfusion Committee INTRODUCTION The Community Transfusion Committee is a multidisciplinary group that meets to monitor blood utilization practices, establish guidelines for transfusion and discuss relevant transfusion related topics. It is comprised of physicians from local hospitals, invited guests, and community representatives from the hospitals’ transfusion services, nursing services, perfusion services, health information management, and the Nebraska Community Blood Bank. These Guidelines for Transfusion are reviewed and revised biannually by the Community Trans- fusion Committee to ensure that the industry’s most current practices are promoted. The Guidelines are the standard by which utilization practices are evaluated. They are also de- signed to provide helpful information to assist physicians to provide appropriate blood compo- nent therapy to patients. Appendices have been added for informational purposes and are not to be used as guidance for clinical decision making. ADULT RED CELLS A. Indications 1. One of the following a. Hypovolemia and hypoxia (signs/symptoms: syncope, dyspnea, postural hypoten- sion, tachycardia, angina, or TIA) secondary to surgery, trauma, GI tract bleeding, or intravascular hemolysis, OR b. Evidence of acute loss of 15% of total blood volume or >750 mL blood loss, OR c.
    [Show full text]
  • 27. Clinical Indications for Cryoprecipitate And
    27. CLINICAL INDICATIONS FOR CRYOPRECIPITATE AND FIBRINOGEN CONCENTRATE Cryoprecipitate is indicated in the treatment of fibrinogen deficiency or dysfibrinogenaemia.1 Fibrinogen concentrate is licenced for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenaemia and hypofibrinogenaemia,2 and is currently funded under the National Blood Agreement. Key messages y Fibrinogen is an essential component of the coagulation system, due to its role in initial platelet aggregation and formation of a stable fibrin clot.3 y The decision to transfuse cryoprecipitate or fibrinogen concentrate to an individual patient should take into account the relative risks and benefits.3 y The routine use of cryoprecipitate or fibrinogen concentrate is not advised in medical or critically ill patients.2,4 y Cryoprecipitate or fibrinogen concentrate may be indicated in critical bleeding if fibrinogen levels are not maintained using FFP. In the setting of major obstetric haemorrhage, early administration of cryoprecipitate or fibrinogen concentrate may be necessary.3 Clinical implications y The routine use of cryoprecipitate or fibrinogen concentrate in medical or critically ill patients with coagulopathy is not advised. The underlying causes of coagulopathy should be identified; where transfusion is considered necessary, the risks and benefits should be considered for each patient. Specialist opinion is advised for the management of disseminated intravascular coagulopathy (MED-PP18, CC-PP7).2,4 y Cryoprecipitate or fibrinogen concentrate may be indicated in critical bleeding if fibrinogen levels are not maintained using FFP. In patients with critical bleeding requiring massive transfusion, suggested doses of blood components is 3-4g (CBMT-PP10)3 in adults or as per the local Massive Transfusion Protocol.
    [Show full text]
  • Long-Term Follow-Up of Thyroid Incidentalomas Visualized with 18F
    diagnostics Article Long-Term Follow-Up of Thyroid Incidentalomas Visualized with 18F-Fluorodeoxyglucose Positron Emission Tomography—Impact of Thyroid Scintigraphy in the Diagnostic Work-Up Kirsten Korsholm 1,*, Michala Reichkendler 1, Louise Alslev 1, Åse Krogh Rasmussen 2 and Peter Oturai 1 1 Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Rigshospitalet, DK-2100 Copenhagen, Denmark; [email protected] (M.R.); [email protected] (L.A.); [email protected] (P.O.) 2 Department of Endocrinology, Copenhagen University Hospital, Rigshospitalet, DK-2100 Copenhagen, Denmark; [email protected] * Correspondence: [email protected] Abstract: Our objective was to evaluate the frequency of malignancy in incidental thyroidal uptake on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in a cohort of Danish patients, and furthermore to evaluate the impact of thyroid scinti-graphy in the diagnostic work-up. All whole-body PET/CT reports from 1 January 2010 to 31 December 2013 Citation: Korsholm, K.; were retrospectively reviewed and further analyzed if visually increased thyroidal FDG uptake was Reichkendler, M.; Alslev, L.; reported. Patient electronic files were searched for further thyroid evaluation. Of 13,195 18F-FDG- Rasmussen, Å.K.; Oturai, P. PET/CT scans in 9114 patients, 312 PET/CT reports mentioned incidental thyroid FDG-uptake, and Long-Term Follow-Up of Thyroid 279 patients were included in the study (3.1%). The thyroid was further investigated in 137 patients Incidentalomas Visualized with 18F-Fluorodeoxyglucose Positron (49%), and 75 patients underwent thyroid scintigraphy. A total of 57 patients had a thyroid biopsy Emission Tomography—Impact of and 21 proceeded to surgery.
    [Show full text]
  • Reference Values for Lung Function Tests in Men: Regression Equations with Smoking Variables
    Upsala J Med Sci 91: 299-310, 1986 Reference Values for Lung Function Tests in Men: Regression Equations with Smoking Variables Hans Hedenstrom, Per Malmberg and Hrafn V. Fridriksson The Department of Clinical Physiology, University Hospital, Uppsala, Sweden, The Research Department, National Board of Occupational Safety and Health, Solna, Sweden, and the Ministry of Health and Social Security, Reykjavik, Iceland ABSTRACT Prediction formulas for static and dynamic spirometry, gas distribution, static lung mechanics and the transfer test were derived from measurements in healthy men. The measurements included total lung capacity, residual volume, airways resistance, static elastic recoil pressure of the lung, static compliance, closing volume, slope of the alveolar plateau (phase 1111, flow-volume variables (including mean transit time) during breathing of air or a helium/oxygen mixture, and conventional spirometric indices. The results from 146 smokers and 124 never-smokers were evaluated separately and combined. For all lung function tests a single regression equation was obtained. The prediction formulas included time-re1 ated smoking variables and were Val id for both smokers and never-smokers. For many lung function tests, a nonlinear age coefficient resulted in a significant reduction in variance compared with.. simple linear models. Heavy tobacco smoking influenced most lung function tests less than ageing from 20 to 70 years, but for airways resistance, transfer factor and phase 111 the opposite was found. INTRODUCTION In research on occupational factors, which may influence pulmonary function, many different lung function tests may be employed in research of early signs of functional impairment. Confounding factors such as age, body size and tobacco smoking must be controlled.
    [Show full text]
  • Cryosupernatant Plasma
    Cryosupernatant Plasma APPLICABILITY: This document applies to Other Names: Cryopoor Plasma AHS, Covenant Health, and all other health Class: Human blood component care professionals involved in the transfusion of blood components and products in Alberta INTRAVENOUS OTHER Intermittent Continuous ROUTES DIRECT IV SC IM OTHER Infusion Infusion Acceptable No Yes No No No N/A Routes* * Professionals performing these restricted activities have received authorization from their regulatory college and have the knowledge and skill to perform the skill competently. DESCRIPTION OF PRODUCT: . Cryosupernatant Plasma (CSP) is prepared from slowly thawed Frozen Plasma that is centrifuged to separate the insoluble cryopreciptate from the plasma. The remaining Cryosupernatant plasma is then refrozen. The approximate volume of a unit is 273 mL . CSP has reduced levels of Factor VIII and von Willebrand Factor (vWF), and does not contain measurable amounts of Factor VIII or fibrinogen. Donors are screened and blood donations are tested for: . ABO/Rh and clinically significant antibodies . Antibodies to human immunodeficiency virus (HIV-1 and HIV-2), hepatitis C virus (HCV), human T-cell lymphotropic virus type I and II (HTLV-I/II), hepatitis B core antigen (HBcore) . Hepatitis B Surface Antigen (HBsAg) . Presence of viral RNA (HIV-1 and HCV) and viral DNA (hepatitis B virus (HBV)) . Syphilis AVAILABILITY: . Not all laboratories/transfusion services stock CSP. Product is stored frozen, and as a result requires preparation time prior to issuing. Patient blood type should be determined when possible to allow for ABO specific/compatible plasma transfusion INDICATIONS FOR USE: . Plasma exchange in patients with Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS).
    [Show full text]
  • Standardised Lung Function Testing
    Thorax: first published as 10.1136/thx.39.12.881 on 1 December 1984. Downloaded from Thorax 1984;39:881-886 Editorial Standardised lung function testing Quality control is an essential ingredient of all clini- Bulletin (Clinical Respiratory Physiology).2 The cal laboratory work and it has been difficult to authors, who are all notable experts in this field, achieve in clinical respiratory physiology. Tests of have tackled all of the problems of standardisation respiratory function call for the active cooperation and produced a series of recommendations which of an untrained individual who has to perform quite are required reading for everyone who is concerned complex manoeuvres on request. To reach the posi- with the organisation of a clinical respiratory tion where different laboratories would produce the laboratory. The recommendations are concerned same result on the same patient, a number of condi- firstly with the performance of the tests and secondly tions have to be met. First, the respiratory man- with the provision of reference values. oeuvres requested must be identical. Secondly, the As the lack of accepted standards has been a apparatus must respond in the same way to the same major problem for epidemiologists concerned with stimulus. Thirdly, the results have to be calculated in lung disease, the National Heart and Lung Institute a standard way and expressed in conventional units. (NHLI) in the United States also embarked on an Finally, the reference or normal values have to be epidemiology standardisation project, eventually agreed between the laboratories, if estimates of the published in full in 1978.3 This document was con- likelihood of normality are to be provided.
    [Show full text]
  • Guidelines for Transfusion and Patient Blood Management, and Discuss Relevant Transfusion Related Topics
    Guidelines for Transfusion and Community Transfusion Committee Patient Blood Management Community Transfusion Committee CHAIR: Aina Silenieks, M.D., [email protected] MEMBERS: A.Owusu-Ansah, M.D. S. Dunder, M.D. M. Furasek, M.D. D. Lester, M.D. D. Voigt, M.D. B. J. Wilson, M.D. COMMUNITY Juliana Cordero, Blood Bank Coordinator, CHI Health Nebraska Heart REPRESENTATIVES: Becky Croner, Laboratory Services Manager, CHI Health St. Elizabeth Mackenzie Gasper, Trauma Performance Improvement, Bryan Medical Center Kelly Gillaspie, Account Executive, Nebraska Community Blood Bank Mel Hanlon, Laboratory Specialist - Transfusion Medicine, Bryan Medical Center Kyle Kapple, Laboratory Quality Manager, Bryan Medical Center Lauren Kroeker, Nurse Manager, Bryan Medical Center Christina Nickel, Clinical Laboratory Director, Bryan Medical Center Rachael Saniuk, Anesthesia and Perfusion Manager, Bryan Medical Center Julie Smith, Perioperative & Anesthesia Services Director, Bryan Medical Center Elaine Thiel, Clinical Quality Improvement/Trans. Safety Officer, Bryan Med Center Kelley Thiemann, Blood Bank Lead Technologist, CHI Health St. Elizabeth Cheryl Warholoski, Director, Nebraska Operations, Nebraska Community Blood Bank Jackie Wright, Trauma Program Manager, Bryan Medical Center CONSULTANTS: Jed Gorlin, M.D., Innovative Blood Resources [email protected] Michael Kafka, M.D., LifeServe Blood Center [email protected] Alex Smith, D.O., LifeServe Blood Center [email protected] Nancy Van Buren, M.D., Innovative
    [Show full text]
  • Strategic Review of Cardiac Physiology Services in England: Final Report
    STRATEGIC REVIEW OF CARDIAC PHYSIOLOGY SERVICES IN ENGLAND: FINAL REPORT Strategic Review of Cardiac Physiology Services in England Page 1 Final Report: 12/05/2015 CONTENTS Page Foreword 3 Summary of recommendations 4 Background 7 Purpose of the Review 8 Working arrangements and governance 8 Delivering a service model for the future 8 Delivering a cardiac physiology service to quality standards 16 Developing a cardiac physiology workforce for the future 18 Commissioning for quality 20 Appendix 1: 23 Cardiac physiology services in summary Appendix 2: 27 Working arrangements and governance Appendix 3: 28 Award in Practical Electrocardiography (APECG) Appendix 4: 29 Proposed possible key performance indicators Appendix 5: 30 Current status of standards development across a range of cardiac physiology investigations Appendix 6: 32 Current training, accreditation and standards Appendix 7: 33 National Review of Cardiac Physiology Services - Modelling the Future Workforce References 34 Glossary 36 Acknowledgements 38 Strategic Review of Cardiac Physiology Services in England Page 2 Final Report: 12/05/2015 FOREWORD In 2013, the Department of Health published the Cardiovascular Outcomes Strategy, a call to action to the health and care systems, which set out ten key actions to deliver for patients with cardiovascular disease improvements in their health outcomes. Cardiac physiology services are key to delivering the improved treatment and care, which is the ambition of the Outcomes Strategy. This Strategic Review of Cardiac Physiology Services was set up to make recommendations to NHS England, Health Education England and across the health and care system about the innovations in service delivery, models of care and workforce configuration which are needed to transform patients’ experience of cardiovascular disease care.
    [Show full text]
  • Department of Clinical Physiology, Nuclear Medicine &
    Department of Clinical Physiology, Nuclear Medicine & PET Annual Report 2019 Rigshospitalet · University of Copenhagen Contents Preface ......................................................................................................................................2 Mission and objectives ...............................................................................................................4 Organisation and staff 2019.......................................................................................................6 Highlights 2019 .......................................................................................................................10 Clinical physiology and nuclear medicine ................................................................................12 PET/CT ..................................................................................................................................14 Artificial intelligence ...............................................................................................................16 Cardiac investigations .............................................................................................................18 Imaging of angiogenesis .........................................................................................................20 Pediatric Nuclear Medicine ......................................................................................................22 Rigshospitalet Children’s Hospital ..................................................................................................................24
    [Show full text]
  • Standardisation of Spirometry
    Eur Respir J 2005; 26: 319–338 DOI: 10.1183/09031936.05.00034805 CopyrightßERS Journals Ltd 2005 SERIES ‘‘ATS/ERS TASK FORCE: STANDARDISATION OF LUNG FUNCTION TESTING’’ Edited by V. Brusasco, R. Crapo and G. Viegi Number 2 in this Series Standardisation of spirometry M.R. Miller, J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, R. Crapo, P. Enright, C.P.M. van der Grinten, P. Gustafsson, R. Jensen, D.C. Johnson, N. MacIntyre, R. McKay, D. Navajas, O.F. Pedersen, R. Pellegrino, G. Viegi and J. Wanger CONTENTS AFFILIATIONS Background ............................................................... 320 For affiliations, please see Acknowledgements section FEV1 and FVC manoeuvre .................................................... 321 Definitions . 321 CORRESPONDENCE Equipment . 321 V. Brusasco Requirements . 321 Internal Medicine University of Genoa Display . 321 V.le Benedetto XV, 6 Validation . 322 I-16132 Genova Quality control . 322 Italy Quality control for volume-measuring devices . 322 Fax: 39 103537690 E-mail: [email protected] Quality control for flow-measuring devices . 323 Test procedure . 323 Received: Within-manoeuvre evaluation . 324 March 23 2005 Start of test criteria. 324 Accepted after revision: April 05 2005 End of test criteria . 324 Additional criteria . 324 Summary of acceptable blow criteria . 325 Between-manoeuvre evaluation . 325 Manoeuvre repeatability . 325 Maximum number of manoeuvres . 326 Test result selection . 326 Other derived indices . 326 FEVt .................................................................. 326 Standardisation of FEV1 for expired volume, FEV1/FVC and FEV1/VC.................... 326 FEF25–75% .............................................................. 326 PEF.................................................................. 326 Maximal expiratory flow–volume loops . 326 Definitions. 326 Equipment . 327 Test procedure . 327 Within- and between-manoeuvre evaluation . 327 Flow–volume loop examples. 327 Reversibility testing . 327 Method .
    [Show full text]
  • Guide to Blood Plasma Products and Their Applications – Part One
    Vet Times The website for the veterinary profession https://www.vettimes.co.uk Guide to blood plasma products and their applications – part one Author : Amanda Boag, Jenny Walton Categories : Vets Date : September 26, 2011 Amanda Boag and Jenny Walton discuss indications for the use of plasma products, their production, and storage within the practice in the first of a three-part series FOLLOWING changes in legislation in 2005, veterinary blood banking and component therapy has developed rapidly within the UK. Practitioners now have easy access to canine blood and its products – notably, packed red cells and various plasma products. This series of articles will focus on indications for plasma product use, their production and storage, the administration and monitoring of plasma transfusions and will include a series of five case studies that have used plasma products. Indications for plasma component therapy Although well-defined indications exist for the use of plasma products in single or multiple coagulation deficiencies, indications for many of its other uses are empiric. Haemostatic disorders Plasma components are most commonly used to treat haemostatic disorders and are generally effective in treating both inherited and acquired conditions. Specific diagnosis enables selection of the optimum replacement product. It is important to remember that any samples drawn for diagnostic purposes (for example, measurement of clotting factor levels) must be taken either 1 / 5 before or at least 36 hours after transfusion to allow the measurement of endogenous levels. Inherited bleeding disorders Plasma components are administered to control active haemorrhage or as preoperative prophylaxis. Inherited bleeding disorders are associated with deficiency of a specific factor and the optimal product for treatment depends on which factor is lacking.
    [Show full text]
  • Ubc Department of Medicine 2005 Annual Report
    UBC DEPARTMENT OF MEDICINE 2005 ANNUAL REPORT TABLE OF CONTENTS MESSAGE FROM DR. GRAYDON MENEILLY….….….….………………………………3 MISSION STATEMENT.……………………………………………………...……………….7 ORGANIZATION CHART.………………………………………………...………………….9 UBC DEPARTMENT OF MEDICINE COMMITTEE STRUCTURES………………..…11 UBC DEPARTMENT OF MEDICINE ADMINISTRATIVE OFFICE...………………….13 UBC DEPARTMENT OF MEDICINE COMMITTEES..………………………………….. 15 Department Heads, Associate Heads, UBC Division Heads, Educational Program Directors & Associate Directors.………………………………………… 17 Research………………………………………………………………………………………….19 Committee for Appointments, Reappointments, Promotion and Tenure.………………………. 21 Teaching Effectiveness Office.…………………………………………………………………..25 DIVISION REPORTS.…………………………………………………………………………27 Allergy & Immunology.………………………………………………………………………… 29 Cardiology.……………………………………………………………………………………….33 Critical Care Medicine.…………………………………………………………………………..45 Dermatology.……………………………………………………………………………………. 49 Endocrinology.………………………………………………………………………………….. 55 Gastroenterology.…………………………………………………………………………….…. 59 General Internal Medicine.……………………………………………………………………… 63 Geriatric Medicine.……………………………………………………………………………… 67 Hematology.…………………………………………………………………………………….. 71 Infectious Diseases.………………………………………………………………………………75 Medical Oncology.……………………………………………………………………………… 81 Nephrology.…………………………………….……………………………………………..… 87 Neurology.……………………………………….…………………………………………….... 93 Occupational Medicine…………………………………………………………………………109 Physical Medicine & Rehabilitation.…………………………………………………………...113 Respiratory
    [Show full text]